Clinical trial
Sorafenib Tosylate in Treating Patients With Progressive Metastatic…
NCT00131911 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00131911 |
|---|---|
| Title | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
| Official title | A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Neuroendocrine Tumor, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma, WDHA Syndrome |
| Intervention type | Drug |
| Interventions | sorafenib tosylate |
| Enrollment | 93 |
| Start date | Jun 1, 2005 |
| Primary completion | Oct 1, 2010 |
| Completion | Apr 1, 2013 |
| First posted | Aug 19, 2005 |
| Last update posted | Nov 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: